CCM
IBER

Context Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Context Capital Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-115,053
Closed -$1.13M – 699
2022
Q1 		$1.13M Buy
+115,053
New +$1.12M 0.07% 311

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Context Capital Management's IBER Position: Q2 2022 in Review

Context Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q2 2022, closing a stake of 115,053 shares — an estimated $1.13M sold.

Context Capital Management first reported a position in IBER in Q1 2022 and held it in 1 quarter. The position peaked at $1.13M in Q1 2022. 46 funds tracked by Wall St. Rank hold IBER as of Q2 2022.

  • Context Capital Management reported no remaining Ibere Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Context Capital Management sold 115,053 Ibere Pharmaceuticals shares in Q2 2022, an estimated $1.13M.
  • Context Capital Management first reported a position in Ibere Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Context Capital Management's Ibere Pharmaceuticals position peaked at $1.13M in Q1 2022.
  • 46 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q2 2022.

Based on Context Capital Management's 13F filing for Q2 2022, filed 3 Aug 2022.